Mary Beth Ritchey, PhD

Director, Epidemiology, Medical Devices

PhD, Epidemiology
MSPH, Epidemiology
BSN, Nursing
University of North Carolina, Chapel Hill, NC

BS, Chemistry
Duke University, Durham, NC

Graduate Certificate, Project Management
Georgetown University, Washington, DC

Mary Beth Ritchey, PhD, is the Principal Epidemiologist for Medical Devices at RTI-HS. In her role at RTI, Dr. Ritchey performs and oversees the scientific, technical, and logistic aspects of projects including postmarketing noninterventional safety and effectiveness studies, analyses of the regulatory landscape for novel therapeutics and rare diseases, and consultation on timing, design, and methodological aspects of real-world studies for medical devices and other therapeutic products. She obtained her doctorate in Epidemiology from the UNC Gillings School of Global Public Heath with concentrations in Pharmacoepidemiology and Infectious Disease. She also has a MSPH in Epidemiology and BS in Nursing from UNC, and an undergraduate degree from Duke University.

Prior to coming to RTI-HS, Dr. Ritchey worked at the Center for Devices and Radiologic Health (CDRH) at the Food and Drug Administration (FDA), where she served as Associate Director for Postmarket Surveillance Studies in the Division of Epidemiology. At the FDA, she managed and oversaw the Postmarket Surveillance Studies (21 CFR 822) and literature review programs and was involved in the Medical Device Epidemiology Network and FDA Sentinel Initiative. After her time with the FDA, she worked in the Comparative and Outcomes Evidence group at Merck enabling development of comparative data strategies through tools, collaborations, and establishing a continuous learning organization for comparative effectiveness research (CER). Immediately prior to coming to RTI, she worked in the global safety group at Procter & Gamble, providing epidemiologic support across the therapeutic and consumer goods portfolio and enhancing the company’s signal management and risk management programs to include interpretation and synthesis across spontaneous adverse events and other safety data sources. Dr. Ritchey has experience with database analyses, literature reviews, utilization and safety surveillance of therapeutic products, registry implementation and governance, and practical application of advanced research methods.

Dr. Ritchey is an active member in the International Society of Pharmacoepidemiology (ISPE), having served on the Scientific Program Committee since 2010, functioned as pre-conference course faculty since 2011, and participated within multiple committees and significant interest groups. She served as the Scientific Program Chair for the annual ISPE meeting in 2016.